CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content


Last Updated: March 8, 2013
Result type: Reports
Project Number: SR0319-000
Product Line: Reimbursement Review

Generic Name: Mirabegron

Brand Name: Myrbetriq

Manufacturer: Astellas Pharma Canada, Inc.

Therapeutic Area: Overactive bladder

Indications: Bladder, Overactive

Submission Type: Initial

Project Status: Withdrawn